Richard H. Weisler, MD

Utilizing the DSM-5 Anxious Distress Specifier to Develop Treatment Strategies for Patients With Major Depressive Disorder

November 28, 2017

Many of your patients with depression also experience anxiety symptoms, and addressing these symptoms is a crucial part of successful treatment. Explore this free Academic Highlights activity to learn...

Michael E. Thase, Richard H. Weisler, J. Sloan Manning, et al

Original Research

Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/ Hyperactivity Disorder Who Report Clinically Significant Impairment in Executive Function: Results From a Randomized, Double-Blind, Placebo-Controlled Study

July 15, 2013

Lenard A. Adler, Bryan Dirks, Patrick F. Deas, et al

Article

Treating Attention-Deficit/Hyperactivity Disorder in Adults: Focus on Once-Daily Medications

November 17, 2011

The objective of this study is to review the efficacy, safety, and abuse potential of approved treatments in adults with attention-deficit/hyperactivity disorder, with a focus on once-daily medications.

Richard H. Weisler, Ann C. Childress

Original Research

Continuation of Quetiapine Versus Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I Disorder (Trial 144: A Randomized Controlled Study)

November 15, 2011

Richard H. Weisler, Willem A. Nolen, Anders Neijber, et al

Article

Posttraumatic Stress Disorder Screening Practices: A 2010 Internet Assessment of Customary Care

September 22, 2011

Posttraumatic stress disorder (PTSD) is a prevalent among returning soldiers and US National Guard and Reserve members. The goal of this descriptive study was to assess customary PTSD screening...

Jennifer J. Brown, Richard H. Weisler

Commentary

A National Epidemic of Unintentional Prescription Opioid Overdose Deaths: How Physicians Can Help Control It

April 19, 2011

Leonard J. Paulozzi, Richard H. Weisler, Ashwin A. Patkar

Article

How Do You Choose a Second-Line Treatment Option for Depression?

October 15, 2010

Richard H. Weisler

Article

How Do You Choose a Second-Line Treatment Option for Depression?

October 15, 2010

Richard H. Weisler

Original Research

A Double-Blind, Placebo-Controlled Study of Quetiapine and Paroxetine as Monotherapy in Adults With Bipolar Depression (EMBOLDEN II)

January 26, 2010

Susan L. McElroy, Richard H. Weisler, William Chang, et al

Original Research

Short-Term Effects of Lisdexamfetamine Dimesylate on Cardiovascular Parameters in a 4-Week Clinical Trial in Adults With Attention-Deficit/Hyperactivity Disorder

December 15, 2009

Lenard A. Adler, Richard H. Weisler, David W. Goodman, et al

Original Research

Attention-Deficit/Hyperactivity Disorder-Specific Quality of Life With Triple-Bead Mixed Amphetamine Salts (SPD465) in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study

November 30, 2008

Thomas J. Spencer, Jeanne M. Landgraf, Lenard A. Adler, et al

Original Research

Triple-Bead Mixed Amphetamine Salts (SPD465), a Novel, Enhanced Extended-Release Amphetamine Formulation for the Treatment of Adults With ADHD: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study

September 30, 2008

Thomas J. Spencer, Lenard A. Adler, Richard H. Weisler, et al

Utilizing the DSM-5 Anxious Distress Specifier to Develop Treatment Strategies for Patients With Major Depressive Disorder

Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/ Hyperactivity Disorder Who Report Clinically Significant Impairment in Executive Function: Results From a Randomized, Double-Blind, Placebo-Controlled Study

Treating Attention-Deficit/Hyperactivity Disorder in Adults: Focus on Once-Daily Medications

Continuation of Quetiapine Versus Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I Disorder (Trial 144: A Randomized Controlled Study)

Posttraumatic Stress Disorder Screening Practices: A 2010 Internet Assessment of Customary Care

A National Epidemic of Unintentional Prescription Opioid Overdose Deaths: How Physicians Can Help Control It

How Do You Choose a Second-Line Treatment Option for Depression?

How Do You Choose a Second-Line Treatment Option for Depression?

A Double-Blind, Placebo-Controlled Study of Quetiapine and Paroxetine as Monotherapy in Adults With Bipolar Depression (EMBOLDEN II)

Short-Term Effects of Lisdexamfetamine Dimesylate on Cardiovascular Parameters in a 4-Week Clinical Trial in Adults With Attention-Deficit/Hyperactivity Disorder

Attention-Deficit/Hyperactivity Disorder-Specific Quality of Life With Triple-Bead Mixed Amphetamine Salts (SPD465) in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study

Triple-Bead Mixed Amphetamine Salts (SPD465), a Novel, Enhanced Extended-Release Amphetamine Formulation for the Treatment of Adults With ADHD: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study

ELSEWHERE:

FOLLOW US:

Richard H. Weisler, MD

Utilizing the DSM-5 Anxious Distress Specifier to Develop Treatment Strategies for Patients With Major Depressive Disorder

Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/ Hyperactivity Disorder Who Report Clinically Significant Impairment in Executive Function: Results From a Randomized, Double-Blind, Placebo-Controlled Study

Treating Attention-Deficit/Hyperactivity Disorder in Adults: Focus on Once-Daily Medications

Continuation of Quetiapine Versus Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I Disorder (Trial 144: A Randomized Controlled Study)

Posttraumatic Stress Disorder Screening Practices: A 2010 Internet Assessment of Customary Care

A National Epidemic of Unintentional Prescription Opioid Overdose Deaths: How Physicians Can Help Control It

How Do You Choose a Second-Line Treatment Option for Depression?

How Do You Choose a Second-Line Treatment Option for Depression?

A Double-Blind, Placebo-Controlled Study of Quetiapine and Paroxetine as Monotherapy in Adults With Bipolar Depression (EMBOLDEN II)

Short-Term Effects of Lisdexamfetamine Dimesylate on Cardiovascular Parameters in a 4-Week Clinical Trial in Adults With Attention-Deficit/Hyperactivity Disorder

Attention-Deficit/Hyperactivity Disorder-Specific Quality of Life With Triple-Bead Mixed Amphetamine Salts (SPD465) in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study

Triple-Bead Mixed Amphetamine Salts (SPD465), a Novel, Enhanced Extended-Release Amphetamine Formulation for the Treatment of Adults With ADHD: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles